Pharmacologists interested in this arena might also note the marked similarity of cellular location, expression and potential neuro-toxicity of both MSRV and ERVWE1 in MS patients in different studies, which might suggest that both HERV-W members are significantly activated in the cerebral lesions of MS patients. Here, ERVW-1 is linked to myeloid sarcoma.